Title:
MULTIVALENT NUCLEIC ACID VACCINES FOR CORONAVIRUS BASED ON SEQUENCES DERIVED FROM SARS-CoV-2 DELTA AND OMICRON STRAINS
Document Type and Number:
WIPO Patent Application WO/2024/067861
Kind Code:
A1
Abstract:
Provided herein are therapeutic nucleic acid molecules for managing, preventing and/or treating infectious diseases caused by coronavirus. Also provided herein are therapeutic compositions, including vaccines and lipid nanoparticles, comprising the therapeutic nucleic acids and related therapeutic methods and uses. Particularly, provided herein are mRNA vaccines based on sequences derived from SARS-CoV-2 delta and omicron strains.
Inventors:
JI KAI (CN)
QIN QIANSHAN (CN)
GAO PENG (CN)
SONG HAIFENG (CN)
LU XISHAN (CN)
YING BO (CN)
QIN QIANSHAN (CN)
GAO PENG (CN)
SONG HAIFENG (CN)
LU XISHAN (CN)
YING BO (CN)
Application Number:
PCT/CN2023/122894
Publication Date:
April 04, 2024
Filing Date:
September 28, 2023
Export Citation:
Assignee:
SUZHOU ABOGEN BIOSCIENCES CO LTD (CN)
International Classes:
C12N15/113; A61K9/127; A61K39/215
Domestic Patent References:
| WO2022137133A1 | 2022-06-30 | |||
| WO2022144317A1 | 2022-07-07 |
Foreign References:
| US20220202930A1 | 2022-06-30 | |||
| CN115043938A | 2022-09-13 |
Other References:
DAICHI YAMASOBA: "Sensitivity of novel SARS-CoV-2 Omicron subvariants, BA.2.11, BA.2.12.1, BA.4 and BA.5 to therapeutic monoclonal antibodies", BIORXIV, 3 May 2022 (2022-05-03), XP093153103, Retrieved from the Internet DOI: 10.1101/2022.05.03.490409
PANKE QU: "Differential Evasion of Delta and Omicron Immunity and Enhanced Fusogenicity of SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants", BIORXIV, 17 May 2022 (2022-05-17), pages 1 - 27, XP093153106, Retrieved from the Internet DOI: 10.1101/2022.05.16.492158
YANG YANG: "Comparative neutralization profiles of naive and breakthrough infections with Delta, Omicron BA.1 and BA.2 variants of SARS-CoV-2", SIGNAL TRANSDUCTION AND TARGETED THERAPY, vol. 7, no. 1, 9 September 2022 (2022-09-09), pages 316, XP093153108, ISSN: 2059-3635, DOI: 10.1038/s41392-022-01166-w
QIAN WANG: "Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, and BA.5", BIORXIV, 27 June 2022 (2022-06-27), XP093153110, Retrieved from the Internet DOI: 10.1101/2022.05.26.493517
CAO YUNLONG, YISIMAYI AYIJIANG, JIAN FANCHONG, SONG WEILIANG, XIAO TIANHE, WANG LEI, DU SHUO, WANG JING, LI QIANQIAN, CHEN XIAOSU,: "BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection", NATURE, SPRINGER NATURE LIMITED, vol. 608, no. 7923, 18 August 2022 (2022-08-18), pages 593 - 602, XP093128531, ISSN: 0028-0836, DOI: 10.1038/s41586-022-04980-y
LORENZA BELLUSCI: "Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination", NATURE COMMUNICATIONS, NATURE PUBLISHING GROUP, UK, vol. 13, no. 1, 8 August 2022 (2022-08-08), UK, pages 4617, XP093153114, ISSN: 2041-1723, DOI: 10.1038/s41467-022-32298-w
PANKE QU: "Differential Evasion of Delta and Omicron Immunity and Enhanced Fusogenicity of SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants", BIORXIV, 17 May 2022 (2022-05-17), pages 1 - 27, XP093153106, Retrieved from the Internet
YANG YANG: "Comparative neutralization profiles of naive and breakthrough infections with Delta, Omicron BA.1 and BA.2 variants of SARS-CoV-2", SIGNAL TRANSDUCTION AND TARGETED THERAPY, vol. 7, no. 1, 9 September 2022 (2022-09-09), pages 316, XP093153108, ISSN: 2059-3635, DOI: 10.1038/s41392-022-01166-w
QIAN WANG: "Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, and BA.5", BIORXIV, 27 June 2022 (2022-06-27), XP093153110, Retrieved from the Internet
CAO YUNLONG, YISIMAYI AYIJIANG, JIAN FANCHONG, SONG WEILIANG, XIAO TIANHE, WANG LEI, DU SHUO, WANG JING, LI QIANQIAN, CHEN XIAOSU,: "BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection", NATURE, SPRINGER NATURE LIMITED, vol. 608, no. 7923, 18 August 2022 (2022-08-18), pages 593 - 602, XP093128531, ISSN: 0028-0836, DOI: 10.1038/s41586-022-04980-y
LORENZA BELLUSCI: "Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination", NATURE COMMUNICATIONS, NATURE PUBLISHING GROUP, UK, vol. 13, no. 1, 8 August 2022 (2022-08-08), UK, pages 4617, XP093153114, ISSN: 2041-1723, DOI: 10.1038/s41467-022-32298-w
Attorney, Agent or Firm:
NTD UNIVATION INTELLECTUAL PROPERTY AGENCY LTD. (CN)
Download PDF: